Back

MyD-88/NLRP-3 inhibition by dapagliflozin protects against anthracycline and trastuzumab cardiotoxicity in preclinical models

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Cardio-oncology challenges Cardio-Oncology ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Nicola Maurea

National Cancer Institute G.Pascale Foundation IRCCS, Naples (Italy)

4 More presentations in this session

Presentation thumbnail
Biomarker and imaging characterisation of inflammatory atheroma in patients receiving immunotherapy and angiogenesis inhibitors (BIOCAPRI): a prospective study using positron emission tomography
Doctor S. Rankin (Glasgow, GB)
Abstract Slides Video
Presentation thumbnail
Predicting Cardiovascular Risk in Patients with Prostate Cancer Receiving Abiraterone or Enzalutamide by Using Machine Learning
Doctor D. Chen (Taipei, TW)
Abstract Slides Video
Presentation thumbnail
Surveillance of left ventricular function among asymptomatic cancer survivors
Doctor C. Soh (Melbourne, AU)
Abstract Slides Video
Presentation thumbnail
Cardiovascular risk profiling in allogenic hematopoietic stem cell transplantation survivors
Mr M. Mutti (Basel, CH)
Abstract Slides Video

Access the full session

Session thumbnail
Cardio-oncology challenges

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
SGLT2 inhibitors and cardiotoxicity in diabetic patients receiving anthracycline therapy: a retrospective study
thumbnail
Congress Presentation
NLRP3/IL-1 pathway was reduced by semaglutide and dapagliflozin in association therapy under exposure to anthracyclines in hyperglycemic conditions
thumbnail
Congress Presentation
The role of statins and SGLT2 inhibitors

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources